IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

Humans Carcinoma, Squamous Cell / drug therapy Skin Neoplasms / drug therapy Interleukin-6 Prognosis Retrospective Studies

Cemiplimab Cutaneous squamous cell carcinoma IL-6 Prognostic factor

Journal

Journal of translational medicine

ISSN: 1479-5876

Titre abrégé: J Transl Med

Pays: England

ID NLM: 101190741

Informations de publication

Date de publication:
23 02 2023

Historique:

received: 12 12 2022

accepted: 05 02 2023

entrez: 24 2 2023

pubmed: 25 2 2023

medline: 3 3 2023

Statut: epublish

Résumé

Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment. Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study. Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy. Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.

Sections du résumé

BACKGROUND

METHODS

Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study.

RESULTS

Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy.

CONCLUSIONS

Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.

Identifiants

DOI: 10.1186/s12967-023-03971-5 PMID: 36823670 PMC: PMC9948392

pubmed: 36823670

doi: 10.1186/s12967-023-03971-5

pii: 10.1186/s12967-023-03971-5

pmc: PMC9948392

doi:

Substances chimiques

cemiplimab 6QVL057INT

Interleukin-6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

140

Informations de copyright

Références

Goodman DT. Cemiplimab and cutaneous squamous cell carcinoma: from bench to bedside. JPRAS Open. 2022;33:155–60. https://doi.org/10.1016/j.jpra.2022.06.003 .

doi: 10.1016/j.jpra.2022.06.003 pubmed: 36046255 pmcid: 9421083

Argenziano G, Fargnoli MC, Fantini F, Gattoni M, Gualdi G, Pastore F, et al. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion. Ther Adv Med Oncol. 2022;14:17588359211066272. https://doi.org/10.1177/17588359211066272 .

doi: 10.1177/17588359211066272 pubmed: 35035534 pmcid: 8753075

Mueller MM. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer. 2006;42:735–44. https://doi.org/10.1016/j.ejca.2006.01.014 .

doi: 10.1016/j.ejca.2006.01.014 pubmed: 16527478

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. https://doi.org/10.1016/j.cell.2010.01.025 .

doi: 10.1016/j.cell.2010.01.025 pubmed: 20303878 pmcid: 2866629

He Z, Wang J, Zhu C, Xu J, Chen P, Jiang X, et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Cancer Lett. 2022;548:215751. https://doi.org/10.1016/j.canlet.2022.215751 .

doi: 10.1016/j.canlet.2022.215751 pubmed: 35718269

Li W, Wu Z, Meng W, Zhang C, Cheng M, Chen Y, et al. Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy. Cytokine. 2022;158:155976. https://doi.org/10.1016/j.cyto.2022.155976 .

doi: 10.1016/j.cyto.2022.155976 pubmed: 35921790

Klein JP, Moeschberger ML. Survival analysis. Berlin: Springer; 2003.

doi: 10.1007/b97377

Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29–41. https://doi.org/10.2307/2530286 .

doi: 10.2307/2530286

Li T, Liu M, Dai H, Li X, Liao J, Zheng Z, et al. Value of cytokine expression in early diagnosis and prognosis of tumor metastasis. J Oncol. 2022;2022:8112190. https://doi.org/10.1155/2022/8112190 .

doi: 10.1155/2022/8112190 pubmed: 36157224 pmcid: 9507706

Xu M, Zhao Z, Song J, Lan X, Lu S, Chen M, Wang Z, Chen W, Fan X, Wu F, Chen L, Tu J, Ji J. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer. Exp Cell Res. 2017;351(2):142–9. https://doi.org/10.1016/j.yexcr.2017.01.008 .

doi: 10.1016/j.yexcr.2017.01.008 pubmed: 28109867

Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD, Chen MF. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 2010;76(4):1214–24. https://doi.org/10.1016/j.ijrobp.2009.09.059 .

doi: 10.1016/j.ijrobp.2009.09.059 pubmed: 20206020

Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8:e000842. https://doi.org/10.1136/jitc-2020-000842 .

doi: 10.1136/jitc-2020-000842 pubmed: 32581042 pmcid: 7312339